It was shown that sorafenib treatment induced PHGDH and activated SSP, and a PHGDH inhibitor NCT-503 synergized with sorafenib to inhibit in vivo growth of HCC tumors [90]. Here, PHGDH is linked to hepatocellular carcinoma.